JB
GBT

Julian Baker’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Julian Baker’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,732,502
Closed -$254M – 128
2022
Q3 		$254M Hold
3,732,502
– – 1.66% 7
2022
Q2 		$119M Buy
3,732,502
+417,737
+13% +$12.2M 0.68% 10
2022
Q1 		$115M Hold
3,314,765
– – 0.66% 12
2021
Q4 		$97M Buy
3,314,765
+97,324
+3% +$3.01M 0.47% 18
2021
Q3 		$82M Hold
3,217,441
– – 0.36% 23
2021
Q2 		$113M Hold
3,217,441
– – 0.49% 19
2021
Q1 		$131M Buy
3,217,441
+2,297,066
+250% +$106M 0.57% 17
2020
Q4 		$39.9M Hold
920,375
– – 0.15% 41
2020
Q3 		$50.7M Buy
920,375
+873,375
+1,858% +$55.5M 0.2% 31
2020
Q2 		$2.97M Hold
47,000
– – 0.01% 91
2020
Q1 		$2.4M Buy
+47,000
New +$3.15M 0.01% 86
2016
Q2 		– Sell
-600,000
Closed -$9.52M – 141
2016
Q1 		$9.52M Buy
600,000
+200,000
+50% +$3.55M 0.1% 57
2015
Q4 		$12.9M Buy
400,000
+200,000
+100% +$8.66M 0.11% 58
2015
Q3 		$8.43M Buy
+200,000
New +$9.44M 0.08% 66

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Julian Baker's GBT Position: Q4 2022 in Review

Julian Baker sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 3,732,502 shares — an estimated $254M sold.

Julian Baker first reported a position in GBT in Q3 2015 and held it in 14 quarters. The position peaked at $254M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Julian Baker reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Julian Baker sold 3,732,502 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $254M.
  • Julian Baker first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 14 quarters.
  • Julian Baker's Global Blood Therapeutics, Inc. position peaked at $254M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.